oncology – Medxy AI

Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic

By MedXY 04/22/2026

A cohort study of over 1 million cancer patients revealed significant reductions in 1-year survival rates during 2020-2021 compared to pre-pandemic trends, with an estimated 17,390 excess cancer deaths attributable to pandemic-related care disruptions.

Diabetes & Endocrinology news Oncology

Three Modifiable Factors Predict Emotional Impairment in Thyroid Cancer Patients: What Clinicians Need to Know

By MedXY 04/13/2026

A prospective study identifies exhaustion, head and neck discomfort, and body image concerns as independent predictors of poor emotional functioning in differentiated thyroid carcinoma patients. These findings highlight actionable targets for prehabilitation and rehabilitation programs.

Clinical Updates news Oncology

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

By MedXY 03/31/2026

This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.

Gastroenterology news Oncology

Spatial Profiling of Resistance Mechanisms in HER2-Positive Gastric Cancer: Insights from Patient-Matched Analysis

By MedXY 03/27/2026

This report examines spatial transcriptomic data from HER2+ gastric cancer patients to identify resistance mechanisms to trastuzumab and T-DXd, including EMT and ERAD pathway activation.

news Oncology Otorhinolaryngology

Liquid Biopsy Predicts Recurrence in HPV-Independent Head and Neck Cancer Months Before Imaging

By MedXY 03/23/2026

A prospective study demonstrates that tumor-informed ctDNA-based minimal residual disease (MRD) testing significantly predicts recurrence and survival in HPV-independent HNSCC, offering a median five-month lead time over clinical detection and standard imaging.

news Oncology

Exploring Diagnostic Delays for Gynecologic and Breast Cancers Following Emergency Department Visits

By MedXY 03/23/2026

This study analyzes how cancer diagnosis timing varies after an emergency department visit, finding that breast cancer faces the longest delays while ovarian cancer is often diagnosed immediately. Factors like comorbidities and primary care access significantly influence these diagnostic intervals.

$Head and Neck Metastases From Infraclavicular Primary Tumors: Analysis of 136 Cases$

news Oncology Otorhinolaryngology

Head and Neck Metastases From Infraclavicular Primary Tumors: Analysis of 136 Cases

By MedXY 03/18/2026

This clinical analysis of 136 patients highlights that head and neck metastases often serve as the primary manifestation of infraclavicular cancers, emphasizing the diagnostic value of cervical lymph nodes.

General Surgery news Oncology

The Bottom-Up Revolution: How New Surgical Techniques are Saving Lives and Lifestyles in Rectal Cancer

By MedXY 03/18/2026

A groundbreaking North American trial reveals that the taTME 'bottom-up' surgical approach for rectal cancer offers a 93.7% three-year survival rate and allows 97% of patients to remain stoma-free, fundamentally changing the landscape of pelvic surgery.

Clinical Updates news Oncology Transplantation

Malignancy Risk Patterns in Solid Organ Transplant Recipients with a History of Pretransplant Cancer

By MedXY 03/14/2026

A large-scale cohort study reveals that solid organ transplant recipients with pre-existing cancer histories face significantly elevated risks for subsequent malignancies, particularly recurring or de novo cancers of the same type, necessitating targeted screening protocols.

news Oncology Respiratory

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

By MedXY 03/13/2026

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional apnea indices to improve prognostic accuracy and patient care.

General Surgery news Oncology Otorhinolaryngology

Long-Term Survival Outweighs Short-Term Quality of Life: Why Esophagectomy Remains the Gold Standard for Esophageal Cancer Responders

By MedXY 03/13/2026

A decision analytical model reveals that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy provides superior 5-year survival and quality-adjusted life-years (QALYs) for esophageal cancer patients achieving clinical complete response after neoadjuvant therapy.

news Oncology

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?

By MedXY 03/13/2026

A large-scale cohort study of over 15,000 patients reveals that isolated tumor cells (ITCs) in regional lymph nodes do not significantly impact short-term overall survival in epithelial ovarian cancer, despite higher prevalence in low-grade serous carcinomas.

news Oncology Urology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY 03/06/2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standards for recurrent prostate cancer.

Dermatology news Rheumatology

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients

By MedXY 03/04/2026

Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enabling earlier detection and personalized screening.

Gastroenterology news Oncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY 03/04/2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer patients.

news OB/GYN & Women's Health Oncology Radiology

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START

By MedXY 02/25/2026

A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations where dense breast tissue is prevalent.

news Oncology Urology

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

By MedXY 02/22/2026

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible patients with muscle-invasive bladder cancer.

news Oncology Otorhinolaryngology

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

By MedXY 02/20/2026

The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gland malignancies.

news Oncology Otorhinolaryngology

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY 02/19/2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specific baseline comorbidities.

news Oncology

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

By MedXY 02/19/2026

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increasing toxicity and treatment duration.